Roberta A. Hauser
#135,927
Most Influential Person Now
Roberta A. Hauser's AcademicInfluence.com Rankings
Roberta A. Hauserphilosophy Degrees
Philosophy
#6864
World Rank
#9974
Historical Rank
Logic
#3958
World Rank
#5193
Historical Rank
Roberta A. Hauserbiology Degrees
Biology
#9318
World Rank
#12507
Historical Rank
Neuroscience
#1352
World Rank
#1398
Historical Rank
Download Badge
Philosophy Biology
Roberta A. Hauser's Degrees
- PhD Neuroscience University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is Roberta A. Hauser Influential?
(Suggest an Edit or Addition)Roberta A. Hauser's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease (2008) (1513)
- The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
- Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. (1995) (899)
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study (2003) (828)
- A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease. (2009) (526)
- High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor (1997) (493)
- Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease (1995) (396)
- Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. (1999) (356)
- The effect of deprenyl and levodopa on the progression of Parkinson's disease (1995) (341)
- Practice Parameter: Therapies for essential tremor (2005) (340)
- Long-term evaluation of deep brain stimulation of the thalamus. (2006) (329)
- Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease (1998) (296)
- Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD (2003) (295)
- A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014) (294)
- Ropinirole for the treatment of early Parkinson's disease (1997) (290)
- Transplanted dopaminergic neurons develop PD pathologic changes: A second case report (2008) (272)
- Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. (2000) (255)
- Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa (2007) (249)
- A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia (2000) (239)
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
- Manganese intoxication and chronic liver failure (1994) (229)
- Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. (1999) (228)
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions (2008) (226)
- Occupation and risk of parkinsonism: a multicenter case-control study. (2009) (225)
- A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease (2006) (224)
- Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study (2005) (219)
- A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (2011) (207)
- Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment (2005) (207)
- Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions. (1988) (206)
- A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
- Bilateral human fetal striatal transplantation in Huntington’s disease (2002) (201)
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations (2008) (199)
- Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration (2009) (195)
- Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson'd Disease: Final 12-Month, Open-Label Results (2014) (187)
- Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. (2015) (178)
- Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
- Adenosine, adenosine A 2A antagonists, and Parkinson's disease. (2009) (173)
- Levodopa: Past, Present, and Future (2008) (172)
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (2017) (171)
- Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes (2013) (165)
- Parkinson's disease home diary: Further validation and implications for clinical trials (2004) (164)
- A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics (2008) (158)
- Pramipexole‐induced somnolence and episodes of daytime sleep (2000) (158)
- Mutant huntingtin is present in neuronal grafts in huntington disease patients (2014) (157)
- Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial (2013) (156)
- Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. (2006) (155)
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial (2011) (154)
- Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study (2004) (151)
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs (2018) (148)
- Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial (2011) (144)
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
- Sertraline for the treatment of depression in parkinson's disease (1997) (135)
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial (2017) (132)
- Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease (2009) (132)
- Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) (2015) (131)
- Determination of minimal clinically important change in early and advanced Parkinson's disease (2011) (130)
- AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study (2013) (130)
- Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa (1998) (124)
- Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease (2009) (123)
- Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) (2017) (123)
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (121)
- Droxidopa for the Short‐Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B) (2015) (118)
- Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease (2000) (112)
- Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial (2014) (109)
- NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study (2015) (108)
- Blood Manganese Correlates with Brain Magnetic Resonance Imaging Changes in Patients with Liver Disease (1996) (107)
- Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients (2004) (104)
- Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease (2009) (103)
- Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations (2010) (99)
- Driving safety in Parkinson’s disease (2002) (99)
- Extended-release pramipexole in advanced Parkinson disease (2011) (98)
- Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial (2014) (93)
- Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets (2016) (92)
- Wearing‐off scales in Parkinson's disease: Critique and recommendations (2011) (92)
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia (2017) (92)
- Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease (2011) (91)
- Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease (2010) (89)
- The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. (2010) (88)
- Randomized trial of cognitive speed of processing training in Parkinson disease (2013) (87)
- Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. (2013) (83)
- Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease (2010) (83)
- Head injury, alpha‐synuclein Rep1, and Parkinson's disease (2012) (83)
- Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. (2014) (82)
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study) (2012) (82)
- Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. (1998) (81)
- Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). (2014) (80)
- Ropinirole for restless legs syndrome (2004) (80)
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. (2015) (80)
- Extended-release pramipexole in early Parkinson disease (2011) (80)
- A randomized trial of inhaled levodopa (CVT‐301) for motor fluctuations in Parkinson's disease (2016) (78)
- Nonmotor symptoms of Parkinson’s disease (2006) (77)
- A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor (2007) (76)
- Autonomic nervous system dysfunction in Parkinson’s disease (2003) (76)
- Which dyskinesia scale best detects treatment response? (2013) (75)
- Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments (2008) (73)
- Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
- Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil (1998) (70)
- Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease (2007) (70)
- Current issues in depression in Parkinson's disease. (1999) (69)
- Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release (2014) (68)
- End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment (2006) (68)
- Magnetic Resonance Imaging of Corticobasal Degeneration (1996) (68)
- Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease (2006) (67)
- Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease (2002) (67)
- Open‐label pilot study of levetiracetam (Keppra) for the treatment of levodopa‐induced dyskinesias in Parkinson's disease (2005) (66)
- Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial (2019) (64)
- Sublingual apomorphine (APL‐130277) for the acute conversion of OFF to ON in Parkinson's disease (2016) (63)
- Bilateral human fetal striatal transplantation in Huntington's disease. (2002) (62)
- Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia (2012) (60)
- A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III) (2017) (60)
- Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model. (1997) (59)
- Future Treatments for Parkinson's Disease: Surfing the PD Pipeline (2011) (57)
- Positron emission tomography after fetal transplantation in Huntington's disease (2005) (56)
- Levodopa response in early Parkinson's disease (2009) (56)
- Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study (2019) (55)
- Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Th (2009) (55)
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
- Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. (2004) (54)
- Essential Tremor: Epidemiology, Diagnosis, and Treatment (2004) (54)
- Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
- A pilot, double‐blind, placebo‐controlled trial of pregabalin (Lyrica) in the treatment of essential tremor (2007) (54)
- [123I]FP‐CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes (2012) (53)
- Double‐blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease (2014) (53)
- Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial (2016) (53)
- Neural transplantation in Parkinson's disease. (2000) (53)
- The nosology of tardive syndromes (2018) (52)
- Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease (2000) (51)
- Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease (2007) (50)
- Treatment of Early Parkinson’s Disease (2009) (50)
- Modafinil treatment of pramipexole‐associated somnolence (2000) (50)
- Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension (2016) (50)
- A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. (2013) (49)
- Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. (2003) (49)
- Levodopa-induced Dyskinesia in Parkinson’s disease: Epidemiology, etiology, and treatment (2007) (48)
- Plasma Thiamine Deficiency Associated with Alzheimer's Disease but Not Parkinson's Disease (1998) (48)
- Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
- Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease (2017) (47)
- Peptidoglycan recognition protein genes and risk of Parkinson's disease (2014) (47)
- Adenosine A2A Receptor Antagonists for Parkinson’s Disease (2005) (46)
- Pioglitazone in early Parkinson's disease (2015) (45)
- Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease (2013) (44)
- Phenomenology and treatment of tremor disorders. (2001) (44)
- Duodenal levodopa infusion for the treatment of Parkinson’s disease (2007) (44)
- Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease (2016) (44)
- Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease (2007) (43)
- Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Th (2005) (43)
- Randomized, controlled trial of rasagiline as an add‐on to dopamine agonists in Parkinson's disease (2014) (42)
- Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients (2016) (42)
- A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients (1998) (41)
- Trial of Prasinezumab in Early-Stage Parkinson's Disease. (2022) (41)
- Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects (2010) (41)
- Neural transplantation for the treatment of Huntington's disease. (2000) (40)
- Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey (2019) (40)
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study (2017) (40)
- Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. (2013) (40)
- Social Security Disability Insurance (SSDI) in Parkinson's disease (2007) (37)
- Long‐term effects of rasagiline and the natural history of treated Parkinson's disease (2016) (37)
- Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials (2011) (37)
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. (2012) (36)
- Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease (2010) (36)
- The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated with Levodopa Alone or with Entacapone: Effects of Vitamin Status (2006) (36)
- Patient Evaluation of a Home Diary to Assess Duration and Severity of Dyskinesia in Parkinson Disease (2006) (36)
- Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with parkinson's disease (1993) (35)
- Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia (2018) (35)
- Caffeine and Progression of Parkinson Disease (2008) (33)
- Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia (2019) (33)
- Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease (2010) (33)
- Levodopa/carbidopa/entacapone in Parkinson’s disease (2009) (33)
- Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. (1998) (32)
- Advances in the Pharmacologic Management of Early Parkinson Disease (2007) (31)
- New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. (2009) (31)
- Long-Term Efficacy of Rasagiline in Early Parkinson's Disease (2010) (30)
- Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial (2012) (30)
- Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. (2014) (30)
- Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease (2021) (30)
- Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease (2006) (29)
- Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. (2019) (29)
- Medical Management and Prevention of Motor Complications in Parkinson’s Disease (2020) (29)
- The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. (2001) (28)
- Dyskinesia Matters (2019) (28)
- Sertraline‐induced exacerbation of Tics in Tourette's syndrome (1995) (28)
- Prevalence and treatment of non-motor symptoms in Parkinson's disease. (2007) (28)
- Early pharmacologic treatment in Parkinson's disease. (2010) (28)
- Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. (2006) (27)
- Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder (2003) (27)
- Initial Management of Parkinson’s Disease (2002) (26)
- Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort (2017) (26)
- Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls (2019) (26)
- Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease (2009) (26)
- Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
- Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease (2014) (25)
- Substantial improvement in a Meige's syndrome patient with levetiracetam treatment (2004) (25)
- Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease (2013) (24)
- IPX066: a novel carbidopa–levodopa extended-release formulation (2012) (24)
- A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease (2017) (24)
- Adult Chediak‐Higashi Parkinsonian syndrome with dystonia (2000) (24)
- The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. (2020) (24)
- Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine (2015) (23)
- Tardive dyskinesia: Out of the shadows (2018) (23)
- Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. (2006) (23)
- Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. (2009) (23)
- Clinical trials aimed at detecting neuroprotection in Parkinson’s disease (2006) (23)
- Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary (2021) (22)
- Optimizing bioavailability in the treatment of Parkinson's disease (2007) (22)
- Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. (1996) (22)
- Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging (2014) (22)
- Effects of rasagiline on the progression of nonmotor scores of the MDS‐UPDRS (2015) (22)
- Ropinirole therapy for Parkinson’s disease (2004) (22)
- GCH1 in early‐onset Parkinson's disease (2009) (22)
- Pregabalin (Lyrica) in the treatment of essential tremor (2007) (22)
- Targeting neurons in the gastrointestinal tract to treat Parkinson's disease☆ (2019) (21)
- Sleep Attacks and Dopamine Agonists for Parkinson’s Disease (2003) (21)
- Clozapine withdrawal symptoms in a Parkinson's disease patient (2002) (21)
- Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studies. (2000) (21)
- Design of a cluster-randomized minority recruitment trial: RECRUIT (2017) (21)
- Levetiracetam for the treatment of generalized dystonia. (2005) (21)
- Depression in Parkinson’s disease (2002) (20)
- Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. (2017) (20)
- Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials (2018) (20)
- Magnetic Resonance Imaging of Neurodegenerative Diseases (1994) (19)
- Use of nutritional supplements in Parkinson's disease patients (2006) (19)
- The effect of L‐dopa infusions with and without phenylalanine challenges in parkinsonian patients (1993) (19)
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs (2018) (18)
- Carbidopa levodopa enteral suspension (2015) (18)
- Caffeine, creatine, GRIN2A and Parkinson's disease progression (2017) (18)
- AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies (2013) (18)
- Management of essential tremor (2002) (18)
- A phase 2, placebo-controlled, randomized, double-blind trial of tozadenant (Syn-115) in patients with Parkinson's disease with wearing-off fluctuations on levodopa (2013) (17)
- Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations (2010) (16)
- An update on Parkinson's disease: improving patient outcomes. (2014) (16)
- Mobility, mood and site of care impact health related quality of life in Parkinson's disease. (2014) (16)
- A2A Receptor Antagonism and Dyskinesia in Parkinson's Disease (2012) (15)
- Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias. (2006) (15)
- Neurosurgery for Parkinson's disease. (2001) (15)
- Infectious issues in human fetal neural transplantation. (1997) (15)
- Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies (2016) (15)
- EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease (2020) (15)
- A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson’s Disease (2021) (15)
- Chorea in a patient with cerebral palsy: Treatment with levetiracetam (2005) (14)
- Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes (2014) (14)
- Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease (2021) (14)
- Management of early Parkinson's disease. (1999) (14)
- Initial experience with electroconvulsive therapy for progressive supranuclear palsy (1994) (14)
- Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review (2020) (14)
- Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice (2020) (13)
- Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease* (2011) (13)
- ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. (2017) (13)
- A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia (2018) (13)
- Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. (2017) (13)
- Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America (2021) (12)
- Neurology: Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease (2007) (12)
- Transplantation of testis-derived sertoli cells into the brain (1996) (12)
- Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease (2013) (12)
- Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
- Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.087) (2014) (12)
- A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia (2016) (12)
- Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease (2018) (12)
- Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials (2021) (12)
- Diffuse lewy body disease (2001) (11)
- Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials (2019) (11)
- Delayed Thalamic Intracranial Hemorrhage in an Essential Tremor Patient following Deep Brain Stimulation (2008) (11)
- Levetiracetam for the treatment of essential tremor (2005) (11)
- The Narrowing Path for Nilotinib and Other Potential Disease-Modifying Therapies for Parkinson Disease. (2019) (11)
- A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. (2020) (11)
- Review: Improving symptom control in early Parkinson’s disease (2009) (11)
- Sleep disorders in Parkinson’s disease (2009) (10)
- Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies (2020) (10)
- Efficacy of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's Disease (P2.335) (2016) (10)
- Botulinum toxin A for the treatment of cervical dystonia (2004) (10)
- Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data (2016) (10)
- The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson's Disease (2012) (10)
- Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double‐blind, placebo‐controlled multicenter study (2017) (10)
- Chorea as a side effect of gabapentin (Neurontin®) in a patient with complex regional pain syndrome Type 1 (2008) (9)
- Tiagabine and exacerbation of essential tremor (2007) (9)
- Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease (2018) (9)
- Will fetal striatal transplants correct the akinetic end-stage of Huntington's disease? (1996) (9)
- Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia (2021) (8)
- Sensitivity, Specificity, Positive and Negative Predictive Values and Diagnostic Accuracy of DaTscan™ (Ioflupane I123 Injection): Predicting Clinical Diagnosis in Early Clinically Uncertain Parkinsonian Syndrome (2014) (8)
- Levetiracetam-induced parkinsonism in a Huntington disease patient. (2005) (8)
- Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson’s disease: a case series (2009) (8)
- MEDICAL TREATMENT OF MOTOR AND NONMOTOR FEATURES OF PARKINSON'S DISEASE (2007) (8)
- Communicating with participants during the conduct of multi-center clinical trials (2016) (8)
- Chorea Induced by Lamotrigine (2006) (8)
- Depression in Patients with Parkinson’s Disease (2000) (8)
- Fatal transplant cyst. (1999) (8)
- On demand therapy for Parkinson’s disease patients: Opportunities and choices (2021) (8)
- Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours (2011) (8)
- Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whales (2019) (8)
- Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. (2000) (7)
- Treatment of chorea with levetiracetam (2005) (7)
- Occupation and Risk of Parkinsonism (2016) (7)
- P2.109 Piclozotan reduces dyskinesia and OFF time in Parkinson's disease (PD) patients with L-dopa induced motor complications (2009) (7)
- Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease (2017) (7)
- Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. (2019) (7)
- Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease (2022) (7)
- Valbenazine for the treatment of tardive dyskinesia (2017) (7)
- Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice (2021) (7)
- Chorea Induced by Lamotrigine (2006) (7)
- Vascular hemichorea/hemiballismus and topiramate (2006) (6)
- Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004) (2014) (6)
- Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. (2020) (6)
- Manganese and chronic liver disease. (1996) (6)
- Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension (2016) (6)
- Ropinirole in the treatment of Parkinson's disease. (1999) (6)
- Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. (2016) (6)
- KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia (PL02.003) (2016) (6)
- Fetal Nigral Transplantation in Parkinson’s Disease (1996) (5)
- Occupation and Risk of Parkinsonism A Multicenter (2009) (5)
- Treatment of Early Parkinson’s Disease (2009) (5)
- α-Synuclein in Parkinson's disease: getting to the core of the matter (2015) (5)
- Toward the use of surgical placebo-controlled trials. (1997) (5)
- Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial (2021) (5)
- Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study (2021) (5)
- Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities (S56.006) (2017) (4)
- Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. (2015) (4)
- Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia (2021) (4)
- Parkinsons Disease Home Diary: Validation and implications for practical use in clinical trials (2004) (4)
- Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease (2017) (4)
- Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) (P2.016) (2017) (4)
- Efficacy and safety of rasagiline in the treatment of Parkinson disease (2006) (4)
- Future therapies for Parkinson's disease. (2004) (4)
- A phase 3 trial evaluating the efficacy, duration of effect, and safety of daxibotulinumtoxinA for injection in the treatment of cervical dystonia (2021) (4)
- Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease (2014) (4)
- Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. (1997) (4)
- Fetal Nigral Transplantation in Parkinson's Disease: The USF Pilot Program (12- to 24-Month Evaluation) (1998) (4)
- Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease (2022) (3)
- Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis (2015) (3)
- Delayed stimulation-induced thalamic ataxia syndrome (1998) (3)
- SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease (2010) (3)
- Medical Management of Parkinson’s Disease (2009) (3)
- Demonstration of a sensory trick in a case of writer's cramp (2002) (3)
- Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. (2020) (3)
- A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia (P2.052) (2018) (3)
- Gocovri Reduces Disruptive Motor Episodes and Improves Function in Parkinson’s Disease Patients With OFF Episodes and Dyskinesia: Analysis of Phase 3 Trial Data (1882) (2020) (3)
- 45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study (2019) (3)
- Safety and Efficacy Study of ADS-5102 (Amantadine HCl) Extended Release Capsules in Levodopa-Induced Dyskinesia (EASED Study) (P4.053) (2014) (3)
- A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpoints (2013) (3)
- A 2 A Receptor Antagonism and Dyskinesia in Parkinson ’ s Disease (2014) (3)
- A Mixed Treatment Comparison (Mtc) To Compare The Efficacy Of Botulinum Toxin Type A Treatments For Cervical Dystonia (2014) (2)
- Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials (2019) (2)
- Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) (S56.007) (2017) (2)
- P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's disease (2009) (2)
- Early therapy for Parkinson's disease. (1991) (2)
- 134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies (2018) (2)
- Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (P4.075) (2018) (2)
- Improved symptom control with fixed dose levodopa/carbidopa/entacapone versus conventional levodopa/carbidopa as first-line levodopa therapy in early Parkinson's disease (pd) patients: P1295 (2008) (2)
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase (P1.017) (2017) (2)
- Inhaled Levodopa Administered With Oral Carbidopa/Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Safety Assessment (S26.005) (2018) (2)
- A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007) (2016) (2)
- Levetiracetam for stiff-person syndrome: report of 2 patients. (2008) (2)
- Inhaled Levodopa Administered With Oral Carbidopa/Levodopa for Early Morning OFF Symptoms in Patients With Parkinson’s Disease: Exploratory Efficacy Analysis (S26.004) (2018) (2)
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF-episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose titration phase (2018) (2)
- Post-hoc Analyses of Phase-3 Data with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.088) (2014) (2)
- Standards Subcommittee of the American Academy of Neurology Practice Parameter: Therapies for essential tremor: Report of the Quality (2009) (2)
- Monoamine Oxidase Inhibitors: Reversible and Irreversible (2002) (2)
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial (2022) (2)
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose-titration phase (2018) (2)
- Levetiracetam (Keppra) in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease (2004) (2)
- Help cure Parkinson’s disease: please don’t waste the Golden Year (2018) (2)
- Thirty Second Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders (2019) (2)
- Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease (2006) (1)
- Double-Blind Study of an Actively-Transported Levodopa Prodrug, XP21279, in Parkinson Disease (P02.075) (2013) (1)
- MODERATO, a randomized, double-blind, placebo-controlled study to assess the effect of rasagiline on mild cognitive impairment in patients with Parkinson’s disease: An ongoing study (P3.027) (2015) (1)
- 134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study (2020) (1)
- Efficacy of rasagiline in early Parkinson’s disease (PD): a meta-analysis of data from the tempo and adagio studies (2015) (1)
- Current treatment challenges and emerging therapies in Parkinson's disease (2004) (1)
- Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy (2021) (1)
- Parkinson's disease and parkinsonism in the elderly: The drug treatment of Parkinson's disease in elderly people (2000) (1)
- Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease (P2.8-048) (2019) (1)
- Initial and disease-modifying strategies in Parkinson’s disease (2013) (1)
- Neural Transplantation and Huntington’s Disease (2000) (1)
- Interim Results from an International, Open-Label Study of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson's Disease: Efficacy Analyses by Subgroups (P01.060) (2013) (1)
- Monoamine oxidase inhibitors (2013) (1)
- Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromes (2014) (1)
- Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine. (2022) (1)
- 34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities (2019) (1)
- Accuracy of DaTscan™ (Ioflupane I 123 Injection) in diagnosis of early parkinsonian syndromes (PS) (2013) (1)
- Deep brain stimulation. Authors' reply (2005) (1)
- COMT Inhibitors in the Treatment of Parkinson’s Disease (2010) (1)
- Efficacy of rasagiline in PD patients with mild cognitive impairment (2016) (1)
- P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease (2022) (1)
- Vascular hemichorea/hemiballismus and topiramate. Author's reply (2006) (1)
- Impact of Reduction in Falls for Patients with PD and nOH: Post Hoc Economic Analyses of Phase 3 Clinical Trial Data on Droxidopa (P1.020) (2016) (1)
- Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment (2022) (1)
- Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia (2020) (1)
- Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) (S56.004) (2017) (1)
- Rotigotine Transdermal System Improves Neuropsychiatric Features (Apathy, Anhedonia, Anxiety, and Depression) and Fatigue in Patients with Parkinson's Disease: A Post-Hoc Analysis of Five Double-Blind Placebo-Controlled Studies (P06.088) (2012) (1)
- Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses (2020) (1)
- Effects of ADS-5102 on non-motor symptoms (NMS) in Parkinson’s disease patients with dyskinesia (P1.039) (2018) (1)
- AbobotulinumtoxinA time to retreatment across indications (2018) (1)
- P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage (2009) (1)
- Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search (2022) (1)
- Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). (2020) (1)
- Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078) (2018) (1)
- DaTSCAN™ (ioflupane I 123 injection), a radiopharmaceutical indicated for visualization of the striatal dopamine transporter using SPECT: Safety profile review (2013) (1)
- Osteopetrosis: a review of a bone disease with neurological sequelae requiring surgical management (1988) (1)
- 46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study (2019) (1)
- Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary®): Results of a Nationwide Dose Conversion Survey (2021) (1)
- Sensitivity, specificity, positive and negative predictive values and accuracy of datscan™/INS; for prediction of clinical diagnosis of early parkinsonian syndromes (2013) (1)
- A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints (2013) (1)
- Sustained efficacy and tolerability of pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (1)
- AbobotulinumtoxinA: Evidence for long duration of response from 5 patient populations (2021) (0)
- A Double-Blind, Randomized Trial of Tegaserod (Zelnorm) in the Treatment of Constipation in Parkinson’s Disease (2004) (0)
- Integrated Efficacy and Safety Analyses of Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension (P1.284) (2015) (0)
- Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003) (2017) (0)
- A Life Shaken: My Encounter With Parkinson's Disease (2002) (0)
- Help cure Parkinson’s disease: please don’t waste the Golden Year (2018) (0)
- O.076 Medical management of early Parkinson's disease (2009) (0)
- Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
- Safety and Efficacy of Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease in a Four-Week Double-blind, Placebo-controlled Randomized Crossover Study (P3.8-036) (2019) (0)
- PROUD stands tall: delayed-start studies in Parkinson's disease (2013) (0)
- Integrated Cardiovascular Safety Profile of Droxidopa (P5.126) (2016) (0)
- Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini (2020) (0)
- Promising medical therapies for Parkinson’s disease (2014) (0)
- Abobotulinumtoxin A dosing in cervical dystonia: An analysis of two large open-label extension studies (2013) (0)
- Inhaled Levodopa (CVT-301) for Treatment of off Periods in Parkinson's Disease: Efficacy as Assessed by 39-Item Parkinson's Disease Quality of Life (QoL) Questionnaire (2019) (0)
- Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia (2022) (0)
- Book Review Parkinson's Disease: The treatment options Edited by Peter A. LeWitt and Wolfgang H. Oertel. 260 pp. London, Martin Dunitz, 1999. £65. 1-85317-379-7 (1999) (0)
- Who is helping whom? Manuscript support and transfer of value (2015) (0)
- The use of cosmetic surgical placebo controlled trials (1996) (0)
- Long-Term Deutetrabenazine Treatment Is Associated With Continued Improvement in Tardive Dyskinesia in the Completed 3-Year Open-Label Extension Study. (2021) (0)
- Symptomatic efficacy of rasagiline in early PD: A meta-analysis (2016) (0)
- Cost Effectiveness of Droxidopa in Patients with Neurogenic Orthostatic Hypotension: Post Hoc Economic Analysis of Phase 3 Trial Data (P2.348) (2016) (0)
- P2.136 Comparative efflcacy and safety of a novel carbidopa–levodopa product (IPX066) and Sinemet in advanced Parkinson's disease (2009) (0)
- 149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study (2018) (0)
- Editorial Board (2016) (0)
- UPDRS motor-score improvement after CVT-301 treatment is associated with improved scores in Parkinson's Disease Questionnaire (PDQ-39) activities of daily living (2020) (0)
- What's Hot in Parkinson's Disease? July 2009 Glutathione Fails to Demonstrate Significant Improvement in Parkinson's Disease Symptoms in a Recently Published Trial (2009) (0)
- P1.016 Neural transplants in patients with Huntington's disease undergo disease-speciflc neuronal degeneration (2009) (0)
- Accelerometry: Variable Correlation with Functional Impact of Tremor (2008) (0)
- Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. (2023) (0)
- 158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study (2018) (0)
- Editorial Advisory Board Co-Editors-in-Chief: (2012) (0)
- EARLY THERAPY FOR PARKINSON'S DISEASE. AUTHORS' REPLY (1991) (0)
- Parkinson's Disease Pathology in Nigral Grafts 14 Years after Transplantation: 865 (2008) (0)
- Minimal Clinically Important Difference in AIMS Score Based on CGIC and PGIC in Patients With Tardive Dyskinesia Treated With Deutetrabenazine. (2021) (0)
- P2.132 Long-term safety and patient preference for dose frequency in patients receiving ropinirole prolonged release in early or advanced Parkinson's disease (2009) (0)
- Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL-130277) in patient with Parkinson’s disease (P1.023) (2017) (0)
- 0617 Solriamfetol Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: Results from a Phase 2 Proof-of-Concept Trial (2019) (0)
- The Clinical Development of Levodopa Inhalation Powder (2023) (0)
- 35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia (2019) (0)
- Sustained off-time decrease in patients using pramipexole extended-release as adjunctive treatment in advanced Parkinson's disease (2010) (0)
- Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease (2022) (0)
- Referat – Add-on-Therapie bei Morbus Parkinson (2015) (0)
- Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders (2022) (0)
- Catechol-O-methyltransferase inhibitors in the treatment of Parkinson’s disease (2012) (0)
- P2.165 Dose-related decrease in “off” time with ropinirole prolonged release in patients with advanced Parkinson's disease (2009) (0)
- No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
- Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study (2022) (0)
- Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study (2022) (0)
- Initial Management of Parkinson's Disease in a Florida Community (2004) (0)
- Reply (2001) (0)
- NDT_A_213917 2205..2212 (2019) (0)
- Efficacy, safety and tolerability of rasagiline as an add-on therapy to dopamine agonists in early Parkinson's disease: The ANDANTE study (2013) (0)
- P2.101 Efflcacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease (2009) (0)
- Efficacy of rasagiline in patients with Parkinson’s disease and mild cognitive impairment: results from moderato, a 24-week randomized, double-blind, placebo-controlled trial (2015) (0)
- 2.263 PATIENT-REPORTED CONVENIENCE OF ONCE-DAILY VS TID DOSING DURING LONG-TERM STUDIES OF PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
- Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study (2021) (0)
- Reliability of the Clinician’s Tardive Inventory (CTI) (2023) (0)
- 151 Confirmed Safety of Deutet.rabenazine for Tardive Dyskinesia in a 3-Year Open-Label Extension Study (2020) (0)
- Article Commentary: Infectious Issues in Human Fetal Neural Transplantation (1997) (0)
- Appendix H: Practice Parameter: Therapies for essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology (2007) (0)
- Reply: Intravenous glutathione in Parkinson's disease (2010) (0)
- Levetiracetam (Keppra) in the Treatment of Choreiform Movements in Huntington's Disease (2005) (0)
- Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
- Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia. (2021) (0)
- Experimental pharmacological agents in the management of Parkinson's disease (2016) (0)
- Number-Needed-to-Treat Analysis of Droxidopa in Patients with Symptomatic Neurogenic Orthostatic Hypotension (P5.125) (2016) (0)
- Strategies for Parkinson’s disease care: prevention and management of motor fluctuations (2011) (0)
- Comparisons among responses to pramipexole extended-release as adjunctive treatment in Japanese and non-Japanese studies of advanced Parkinson's disease (2010) (0)
- Interim results from an international , open-label study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson ’ s disease : efficacy results by country (2012) (0)
- Letter to the editor (1996) (0)
- Poster 350 A Random Effect Mixed Treatment Comparison (MTC) to Compare the Efficacy of Botulinum Toxin Type A Treatments for Cervical Dystonia (2014) (0)
- Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use (2022) (0)
- Efficacy of opicapone in Parkinson's patients with motor fluctuations and ON Hoehn & Yahr ≤2.5: post hoc analysis of BIPARK-1 (2020) (0)
- Serial olfactory testing for the diagnosis of prodromal Parkinson's disease in the PARS study. (2022) (0)
- Patient-reported motor responses to apomorphine sublingual film based on home dosing and response diaries (2020) (0)
- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson’s Disease (2015) (0)
- Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary? (2023) (0)
- AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions (2021) (0)
- Changes to Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with Dyskinesia While on GocovriTM (Amantadine) Extended Release Capsules: a Two-Year Phase 3 Open Label Study Analysis (P4.7-010) (2019) (0)
- Contents Vol. 82, 2019 (2020) (0)
- P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's disease (2009) (0)
- 0581 Sleep Patterns and “OFF”-Time in Patients with Parkinson’s Disease and Motor Fluctuations (2022) (0)
- 2.265 LONG-TERM SAFETY AND SUSTAINED EFFICACY OF EXTENDED-RELEASE PRAMIPEXOLE IN EARLY AND ADVANCED PARKINSON'S DISEASE (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Roberta A. Hauser?
Roberta A. Hauser is affiliated with the following schools:
